Cargando…
The Impact of Concomitant Proton Pump Inhibitors on Immunotherapy Efficacy among Patients with Urothelial Carcinoma: A Meta-Analysis
Background. Immune checkpoint inhibitors (ICIs) have recently represented a breakthrough in urothelial carcinoma (UC). Proton pump inhibitors (PPIs) are routinely used for extended time periods in UC patients, with these agents having potentially and frequently undervalued effects on ICIs efficacy....
Autores principales: | Rizzo, Alessandro, Santoni, Matteo, Mollica, Veronica, Ricci, Angela Dalia, Calabrò, Concetta, Cusmai, Antonio, Gadaleta-Caldarola, Gennaro, Palmiotti, Gennaro, Massari, Francesco |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9145929/ https://www.ncbi.nlm.nih.gov/pubmed/35629263 http://dx.doi.org/10.3390/jpm12050842 |
Ejemplares similares
-
Current and Future Role of Neoadjuvant Chemoimmunotherapy for Early Triple-Negative Breast Cancer: Which Way to Go Forward
por: Rizzo, Alessandro, et al.
Publicado: (2022) -
Pathologic Complete Response in Urothelial Carcinoma Patients Receiving Neoadjuvant Immune Checkpoint Inhibitors: A Meta-Analysis
por: Rizzo, Alessandro, et al.
Publicado: (2022) -
Impact of Proton Pump Inhibitors and Histamine-2-Receptor Antagonists on Non-Small Cell Lung Cancer Immunotherapy: A Systematic Review and Meta-Analysis
por: Rizzo, Alessandro, et al.
Publicado: (2022) -
Pemigatinib in Intrahepatic Cholangiocarcinoma: A Work in Progress
por: Gadaleta-Caldarola, Gennaro, et al.
Publicado: (2022) -
Pathological Complete Response to Neoadjuvant Chemoimmunotherapy for Early Triple-Negative Breast Cancer: An Updated Meta-Analysis
por: Rizzo, Alessandro, et al.
Publicado: (2022)